C4 Therapeutics’ Third Quarter 2026: Cemsidomide Builds Momentum While Cash Keeps the Lights On Through 2028
Ticker: CCCC | EPS (loss per share): $0.16 in Q3 2026 vs $0.44 in Q3 2025 | Revenue: $8.5 million in Q3 2026 | EPS consensus and earnings surprise dynamics remain opaque in a pure-play clinical-stage story
Executive snapshot
The Nasdaq-listed biotech C4 Therapeutics, Inc. (C4T; ticker CCCC) reports continued progress in its pipeline centered on cemsidomide, a cereblon-modulating protein degrader. In the third quarter ended September 30, 2026, the company posted revenue of $8.5 million and a net loss per share (EPS) of $0.16, narrowing from a $0.44 loss in the year-ago quarter. Operating metrics are still a story about advancing trials rather than commercial scale, but the company is laying out a clear path toward upcoming catalysts in 2027.
Cash, cash equivalents, and marketable securities totaled $274.7 million at quarter-end, down from $300.4 million as of June 30, 2026, with management signaling a runway into the end of 2028. That gives investors a reasonably long fuse for late-stage readouts and potential collaborations, even as the company remains several years away from a product revenue inflection.
Financial details
- Revenue: $8.5 million for Q3 2026, versus $11.2 million in Q3 2025. The delta reflects the evolving mix of collaborations (notably Roche Degrader-Antibody Conjugate) and the ongoing transition from early-stage development to later-stage readouts.
- R&D expense: $24.8 million in Q3 2026, down from $26.0 million in Q3 2025. The decline is attributed to lower stock-based compensation but offset by higher clinical activity and advancement of cemsidomide programs.
- G&A expense: $8.3 million in Q3 2026, modestly lower than $8.9 million in Q3 2025, consistent with leaner corporate overhead as programs scale.
- Net loss: $21.8 million for Q3 2026, vs $32.2 million in Q3 2025. Per-share loss was $0.16, an improvement over $0.44 in the prior-year quarter.
- Liquidity outlook: Cash and equivalents were $274.7 million as of September 30, 2026, with management projecting funding through the end of 2028 to support ongoing clinical programs and pipeline expansion.
Note: The press release provides no formal EPS consensus or explicit earnings surprise metrics from sell-side analysts. The narrative is dominated by clinical progress and upcoming trial milestones rather than near-term commercial or financial inflection points.
Pipeline and program highlights
The centerpiece remains cemsidomide, a cereblon-modulating degrader targeting IKZF1/3, intended for multiple myeloma (MM) biology. Management underscored several near-term catalysts and program updates:
- Phase 1b in RRMM with elranatamab: The trial combining cemsidomide with elranatamab (ELREXFIO) is progressing in earlier MM lines. The Safety Data Review Committee approved the 75 μg dose to proceed, with an escalation to 100 μg and an expansion cohort at 75 μg. Data from evaluated cohorts are anticipated in mid-2027.
- Phase 2 MOMENTUM: The trial evaluating cemsidomide in combination with dexamethasone in late-line MM remains on track to complete enrollment in 1Q 2027, with initial investigator-assessed ORR data expected in 2H 2027. This is the most visible near-term catalyst on the pipeline horizon.
- Additional Phase 1b arms: An ongoing plan to initiate a two-arm Phase 1b trial in 1H 2027, comparing cemsidomide + dexamethasone + daratumumab vs. cemsidomide + dexamethasone + carfilzomib, with 75 μg starting dose across arms.
- TCD-Disruption and DEL: At the Targeted Protein Degradation Summit (late October 2026), C4T highlighted a DNA-encoded library (DEL) integrated with its TORPEDO platform, aiming to accelerate hit-to-development for cereblon-binding degraders and potentially broaden the company’s discovery engine.
The narrative remains that cemsidomide could emerge as a backbone/combination partner in MM treatment paradigms, potentially enabling durable responses when paired with immune-activating agents.
Upcoming milestones
- 1Q 2027: Complete enrollment of the Phase 2 MOMENTUM trial.
- 2H 2027: Initial ORR data from MOMENTUM expected.
- 1H 2027: Begin additional Phase 1b trial arms in RRMM (three-drug regimens as noted above).
- Mid-2027: Present data from all cohorts evaluated in the Phase 1b trial of cemsidomide with elranatamab.
- Late 2026–2027 (conference season): Updates from IMS and other venues on biomarker and pharmacodynamic signals driving the company’s narrative around immune activation and myeloma control.
Strategic implications and sector outlook
From a storytelling perspective, C4T’s revenue forecast and near-term EPS trajectory remain anchored to trial readouts rather than quarterly revenue lines. The quarter’s improvement in EPS and narrower net loss reinforces the patient capital narrative rather than a near-term profitability thesis. Investors should watch how the MOMENTUM enrollment trajectory translates into meaningful ORR data in 2027, a potential inflection point for MM-focused biotechs that hinge on targeted protein degraders paired with well-established MM regimens.
In the broader sector, the emphasis on combining novel degraders with antibodies (BCMA-directed or otherwise) echoes a trend toward multidrug regimens that seek to convert immune activation into durable disease control. C4T’s DEL platform addition suggests a strategic push to shorten discovery cycles, which could be a differentiator if it yields new development candidates and collaboration opportunities.
Risks remain institutional and clinical: trial delays, safety signals in combination regimens, and the ever-present hurdle of converting strong early signals into durable, label-ready therapies. Still, the balance sheet provides a runway that reduces the need for rapid dilution while trials mature—a favorable setup for patient long-hold investors and potential collaboration partners evaluating risk-adjusted upside.
Company overview and closing thoughts
C4 Therapeutics sits at the intersection of targeted protein degradation and immuno-oncology, with a pipeline that leans into combination strategies rather than stand-alone monotherapies in MM. The Q3 2026 results indicate core operating discipline—lower operating expenses, a stable run-rate on R&D spend, and a meaningful cash buffer for multiple late-stage readouts. The next 12–18 months should reveal whether MOMENTUM’s enrollment cadence and the elranatamab/combinational program can deliver the kind of data inflection that shifts CCCC from narrative-driven excitement to durable, investor-visible value.
For peers in the MM space, C4T’s emphasis on combination strategies and discovery acceleration highlights a broader industry push: prove you can pair solid biological mechanisms with reliable trial design. If DEL proves to be a catalyst for faster candidate generation, expect competitive responses from peers weighing both internal discovery and collaboration-driven routes to value creation.